Isabel Jimenez
Isabel Jimenez has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Kiran Rai
Institute of Applied Health Research, University of Birmingham, Birmingham, UK
3 shared publications Antonia Geneidat
Real-World Evidence, Adelphi Real World, Bollington, UK
2 shared publications- Dexter J. Wiseman
National Heart and Lung Institute, Imperial College London, London, UK
2 shared publications - Dheeraj Sethi
National Heart and Lung Institute, Imperial College London, London, UK
2 shared publications - Jack Said
Access & Value, Pfizer Ltd, Tadworth, UK
2 shared publications - Jonathan Watkins
Real-World Evidence, Adelphi Real World, Bollington, UK
2 shared publications
Latest Publications
- Open Access
- 6 October 2026
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 15 (12) , 3411-3430
Clinical Burden of Disease and Demographics in Older Adults Hospitalized with RSV Infection in England: A Retrospective Cohort Study
- 6 October 2026
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 15 (12) , 3411-3430
Open AccessClinical Burden of Disease and Demographics in Older Adults Hospitalized with RSV Infection in England: A Retrospective Cohort Study
- Open Access
Clinical burden of disease and demographics in older adults hospitalised with RSV infection in England: A retrospective cohort study
Introduction: Respiratory syncytial virus (RSV) causes significant disease in older and comorbid adults. Current UK vaccination recommendations restrict eligibility to adults ≥75-years, 65-74-years with chronic respiratory disease or immunosuppression, and those in care homes, but evidence on clinical burden in adults <75-years with comorbidities is limited. This study assessed patient characteristics, healthcare resource utilisation (HCRU), and mortality in adults hospitalised with RSV in England. Methods: Population-based retrospective cohort study using linked Clinical Practice Research Datalink Aurum and Hospital Episode Statistics. Adults ≥60-years hospitalised with RSV between October 2014-March 2019 were included. RSV episodes defined as 90-days post diagnosis. Case definitions were created using diagnosis codes related to confirmed RSV (RSV-specific) or acute lower respiratory tract infection where other causative pathogens were excluded (RSV-possible). All-cause HCRU (hospitalisations, critical care admissions, outpatient attendance, primary care consultations, and prescriptions) and case fatality rates were assessed. Results were stratified by age (60-74 and ≥75-years), case definitions (RSV-specific, RSV-possible) and comorbidity profiles (chronic respiratory disease, immunocompromised, cardiovascular disease). Results: A total of 97,712 hospitalised episodes in those aged ≥60-years were included in the analysis, where 785 (0.8%) were RSV-specific cases (n=338 aged 60-74-years, n=447 aged ≥75-years). In RSV-specific cases, median (IQR) cumulative length of stay (LoS) for those ≥75-years was 10.00 (6.00-22.00) days which was equivalent to or lower than each comorbidity sub-group in those aged 60-74-years, with longest LoS in those immunocompromised (11.50 [7.00-26.00] days). Critical care admissions were more often observed across comorbidity stratifications (13.85%-22.34%) compared to those ≥75-years (5.03%). All-cause and RSV-related case fatality rates for RSV-specific cases were highest among those ≥75-years (all-cause: 19.3%; RSV-related: 10.3%). Conclusion: HCRU within RSV episodes in those aged 60-74-years across comorbidity profiles was equal to or greater compared to those aged ≥75-years. These findings highlight the need to prioritise consideration of comorbidity groups that could benefit from RSV vaccination. Key summary points: Why carry out this study?: • There is growing evidence on the burden of disease of RSV, however there is still a question around whether everyone at risk of severe outcomes are covered by the UK vaccination programme. • There is a paucity in evidence on the clinical burden of RSV in adults <75-years, especially in those with comorbidities including cardiovascular risk factors. Granular HCRU and morality outcomes are required to inform policy decisions on RSV vaccination strategies in these groups. • This study aimed to quantify the clinical burden of RSV in adults ≥60-years in England, stratified by comorbidity profile and descriptively compare to those previously eligible for the RSV-vaccine programme in England (aged ≥75-years, and in those in adult care homes). What was learned from the study?: • The study found that the clinical burden of RSV in secondary care in adults aged 60-74-years across all comorbidities stratifications, is equivalent to or exceeds the burden of those aged ≥75-years.
Open AccessClinical burden of disease and demographics in older adults hospitalised with RSV infection in England: A retrospective cohort study
Introduction: Respiratory syncytial virus (RSV) causes significant disease in older and comorbid adults. Current UK vaccination recommendations restrict eligibility to adults ≥75-years, 65-74-years with chronic respiratory disease or immunosuppression, and those in care homes, but evidence on clinical burden in adults <75-years with comorbidities is limited. This study assessed patient characteristics, healthcare resource utilisation (HCRU), and mortality in adults hospitalised with RSV in England. Methods: Population-based retrospective cohort study using linked Clinical Practice Research Datalink Aurum and Hospital Episode Statistics. Adults ≥60-years hospitalised with RSV between October 2014-March 2019 were included. RSV episodes defined as 90-days post diagnosis. Case definitions were created using diagnosis codes related to confirmed RSV (RSV-specific) or acute lower respiratory tract infection where other causative pathogens were excluded (RSV-possible). All-cause HCRU (hospitalisations, critical care admissions, outpatient attendance, primary care consultations, and prescriptions) and case fatality rates were assessed. Results were stratified by age (60-74 and ≥75-years), case definitions (RSV-specific, RSV-possible) and comorbidity profiles (chronic respiratory disease, immunocompromised, cardiovascular disease). Results: A total of 97,712 hospitalised episodes in those aged ≥60-years were included in the analysis, where 785 (0.8%) were RSV-specific cases (n=338 aged 60-74-years, n=447 aged ≥75-years). In RSV-specific cases, median (IQR) cumulative length of stay (LoS) for those ≥75-years was 10.00 (6.00-22.00) days which was equivalent to or lower than each comorbidity sub-group in those aged 60-74-years, with longest LoS in those immunocompromised (11.50 [7.00-26.00] days). Critical care admissions were more often observed across comorbidity stratifications (13.85%-22.34%) compared to those ≥75-years (5.03%). All-cause and RSV-related case fatality rates for RSV-specific cases were highest among those ≥75-years (all-cause: 19.3%; RSV-related: 10.3%). Conclusion: HCRU within RSV episodes in those aged 60-74-years across comorbidity profiles was equal to or greater compared to those aged ≥75-years. These findings highlight the need to prioritise consideration of comorbidity groups that could benefit from RSV vaccination. Key summary points: Why carry out this study?: • There is growing evidence on the burden of disease of RSV, however there is still a question around whether everyone at risk of severe outcomes are covered by the UK vaccination programme. • There is a paucity in evidence on the clinical burden of RSV in adults <75-years, especially in those with comorbidities including cardiovascular risk factors. Granular HCRU and morality outcomes are required to inform policy decisions on RSV vaccination strategies in these groups. • This study aimed to quantify the clinical burden of RSV in adults ≥60-years in England, stratified by comorbidity profile and descriptively compare to those previously eligible for the RSV-vaccine programme in England (aged ≥75-years, and in those in adult care homes). What was learned from the study?: • The study found that the clinical burden of RSV in secondary care in adults aged 60-74-years across all comorbidities stratifications, is equivalent to or exceeds the burden of those aged ≥75-years.
- Open Access
- 14 August 2025
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 32 (9) , e70062
Treatment Discontinuation and Adherence in Patients With Chronic Hepatitis B Infection Newly Initiating Nucleos(t)ide Analogues in Japan: A Retrospective Cohort Study
Nucleos(t)ide analogue (NA) therapy is the current standard of care for chronic hepatitis B (CHB) virus infection but rarely achieves functional cure, necessitating long‐term therapy, which often leads to nonadherence and increased treatment burden. This retrospective cohort study was designed to describe treatment discontinuation and adherence to second‐generation NAs among patients with CHB in Japan. We used the Japanese Medical Data Center Claims Database (JMDC Inc.) to identify adults with CHB who were newly initiated on a single‐agent, second‐generation NA between January 2007 and August 2023. Outcomes included treatment discontinuation and adherence, treatment restart after discontinuation, NA switching and factors associated with treatment discontinuation/adherence. Of the 2473 patients included in this study (mean age 49.9 years), 65.6% were male. The most common index NAs were entecavir (55.5%) and tenofovir alafenamide fumarate (TAF, 36.2%). Treatment discontinuation was observed in 20.3% of patients; mean time to discontinuation was 20.4 months. Of the patients who discontinued, 50.7% restarted NAs. Mean adherence (proportion of days covered [PDC]) was 0.87, and 81.2% of participants had PDC ≥ 80%. Age group 35–64 years, index treatment TAF and baseline hepatocellular carcinoma diagnosis were significantly associated with a decreased probability of treatment discontinuation and nonadherence. Although a high proportion of patients were persistent and adherent to NA treatment, there is a subgroup of patients whose needs are not met while receiving NA treatment, particularly in younger age groups. The results emphasise the need for alternative therapies with shorter, finite treatment durations to improve patient persistence, adherence and outcomes.
- 14 August 2025
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 32 (9) , e70062
Open AccessTreatment Discontinuation and Adherence in Patients With Chronic Hepatitis B Infection Newly Initiating Nucleos(t)ide Analogues in Japan: A Retrospective Cohort Study
Nucleos(t)ide analogue (NA) therapy is the current standard of care for chronic hepatitis B (CHB) virus infection but rarely achieves functional cure, necessitating long‐term therapy, which often leads to nonadherence and increased treatment burden. This retrospective cohort study was designed to describe treatment discontinuation and adherence to second‐generation NAs among patients with CHB in Japan. We used the Japanese Medical Data Center Claims Database (JMDC Inc.) to identify adults with CHB who were newly initiated on a single‐agent, second‐generation NA between January 2007 and August 2023. Outcomes included treatment discontinuation and adherence, treatment restart after discontinuation, NA switching and factors associated with treatment discontinuation/adherence. Of the 2473 patients included in this study (mean age 49.9 years), 65.6% were male. The most common index NAs were entecavir (55.5%) and tenofovir alafenamide fumarate (TAF, 36.2%). Treatment discontinuation was observed in 20.3% of patients; mean time to discontinuation was 20.4 months. Of the patients who discontinued, 50.7% restarted NAs. Mean adherence (proportion of days covered [PDC]) was 0.87, and 81.2% of participants had PDC ≥ 80%. Age group 35–64 years, index treatment TAF and baseline hepatocellular carcinoma diagnosis were significantly associated with a decreased probability of treatment discontinuation and nonadherence. Although a high proportion of patients were persistent and adherent to NA treatment, there is a subgroup of patients whose needs are not met while receiving NA treatment, particularly in younger age groups. The results emphasise the need for alternative therapies with shorter, finite treatment durations to improve patient persistence, adherence and outcomes.